

Xavier Anglaret

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8769870/publications.pdf>

Version: 2024-02-01

167
papers

7,776
citations

71102

41
h-index

54911

84
g-index

170
all docs

170
docs citations

170
times ranked

7642
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected West African adults. <i>HIV Medicine</i> , 2022, 23, 717-726.	2.2	1
2	Simplifying and optimising management of acute malnutrition in children aged 6 to 59 months: study protocol for a 3 arms community-based individually randomised controlled trial in decentralised Niger. <i>Trials</i> , 2022, 23, 89.	1.6	8
3	Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults. <i>BMC Infectious Diseases</i> , 2022, 22, 100.	2.9	1
4	Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). <i>Clinical Microbiology and Infection</i> , 2022, 28, 1010-1016.	6.0	21
5	Simplifying and optimising the management of uncomplicated acute malnutrition in children aged 6-59 months in the Democratic Republic of the Congo (OptiMA-DRC): a non-inferiority, randomised controlled trial. <i>The Lancet Global Health</i> , 2022, 10, e510-e520.	6.3	15
6	Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 621-629.	2.0	5
7	Association of Plasma Soluble Vascular Cell Adhesion Molecule-1 and sCD14 With Mortality in HIV-1-Infected West African Adults With High CD4 Counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 138-145.	2.1	6
8	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2666-2674.	3.0	0
9	Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study. <i>The Lancet Global Health</i> , 2021, 9, e469-e478.	6.3	30
10	Research on COVID-19 therapy: Putting the cart alongside the horse. <i>EBioMedicine</i> , 2021, 67, 103342.	6.1	1
11	Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12-300 Replate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Infectious Diseases</i> , 2021, 21, 813-822.	9.1	17
12	Optimising Malnutrition Treatment - OptiMA-DRC: Recovery of Severely Wasted Children 6-59 Months in a Randomised Control Trial in Democratic Republic of Congo. <i>Current Developments in Nutrition</i> , 2021, 5, 110.	0.3	0
13	Optimising Malnutrition Treatment in Children 6-59 Months-OptiMA-DRC: Primary Outcome of a Randomised Control Trial in Democratic Republic of Congo. <i>Current Developments in Nutrition</i> , 2021, 5, 111.	0.3	0
14	Clinical presentation, outcomes and factors associated with mortality: A prospective study from three COVID-19 referral care centres in West Africa. <i>International Journal of Infectious Diseases</i> , 2021, 108, 45-52.	3.3	14
15	Elite and viremic HIV-1 controllers in West Africa. <i>Aids</i> , 2021, Publish Ahead of Print, 29-38.	2.2	0
16	Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4 ⁺ cell counts. <i>Antiviral Therapy</i> , 2021, 26, 25-33.	1.0	4
17	Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. <i>Lancet HIV</i> , 2021, 8, e8-e15.	4.7	31
18	Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). <i>Trials</i> , 2020, 21, 846.	1.6	21

#	ARTICLE	IF	CITATIONS
19	Association between cellular HIV-1 DNA level and mortality in HIV-1 infected African adults starting ART with high CD4 counts. <i>EBioMedicine</i> , 2020, 56, 102815.	6.1	7
20	Simplifying and optimising management of acute malnutrition in children aged 6 to 59 months: study protocol for a community-based individually randomised controlled trial in Kasaï, Democratic Republic of Congo. <i>BMJ Open</i> , 2020, 10, e041213.	1.9	4
21	Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. <i>New England Journal of Medicine</i> , 2020, 382, 2397-2410.	27.0	27
22	HIV, Pregnancy, and Isoniazid Preventive Therapy. <i>New England Journal of Medicine</i> , 2020, 382, 1184-1185.	27.0	4
23	Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 258-271.	2.5	20
24	Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE). <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101557.	3.0	5
25	Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 437-445.	1.8	4
26	Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis. <i>PLoS ONE</i> , 2019, 14, e0219068.	2.5	5
27	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study. <i>Journal of the International AIDS Society</i> , 2019, 22, e25392.	3.0	24
28	Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study. <i>Lancet HIV</i> , 2019, 6, e750-e759.	4.7	15
29	Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 195-202.	4.0	38
30	Effect of hepatitis B virus (HBV) <i>surface</i> gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa. <i>Liver International</i> , 2019, 39, 280-289.	3.9	2
31	CD4+ T Cell Recovery and Hepatitis B Virus Coinfection in HIV-Infected Patients from Côte d'Ivoire Initiating Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 439-445.	1.1	4
32	Twenty-Year Evolution of Hepatitis B Virus and Human Immunodeficiency Virus Prevalence and Incidence in Voluntary Blood Donors in Côte d'Ivoire. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy060.	0.9	9
33	Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV) Coinfected Patients With High HBV Replication. <i>Clinical Infectious Diseases</i> , 2018, 66, 112-120.	5.8	42
34	Reply to Hector et al. <i>Clinical Infectious Diseases</i> , 2018, 67, 1311-1312.	5.8	1
35	I would prefer not to aggravate global warming. <i>Lancet Planetary Health</i> , 2018, 2, e382-e383.	11.4	1
36	Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2018, 218, S496-S503.	4.0	25

#	ARTICLE	IF	CITATIONS
37	Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. <i>The Lancet Global Health</i> , 2017, 5, e80-e88.	6.3	100
38	Severe bacterial infections: overlooked opportunistic diseases. <i>Lancet HIV</i> , 2017, 4, e94-e95.	4.7	2
39	Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. <i>The Lancet Global Health</i> , 2017, 5, e1080-e1089.	6.3	128
40	Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. <i>Annals of Internal Medicine</i> , 2017, 167, 618.	3.9	18
41	Virological efficacy of 24-week fozivudine-based regimen in ART-naïve patients from Tanzania and Côte d'Ivoire. <i>Aids</i> , 2017, 31, 501-509.	2.2	0
42	High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire. <i>PLoS ONE</i> , 2017, 12, e0177440.	2.5	10
43	Prevalence of pulmonary tuberculosis among prison inmates: A cross-sectional survey at the Correctional and Detention Facility of Abidjan, Côte d'Ivoire. <i>PLoS ONE</i> , 2017, 12, e0181995.	2.5	18
44	Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005389.	3.0	153
45	Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005545.	3.0	17
46	Missed opportunities for HIV testing among newly diagnosed HIV-infected adults in Abidjan, Côte d'Ivoire. <i>PLoS ONE</i> , 2017, 12, e0185117.	2.5	13
47	Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus/Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1936-1942.	1.4	7
48	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967.	8.4	382
49	Early antiretroviral therapy initiation in west Africa has no adverse social consequences. <i>Aids</i> , 2016, 30, 1677-1682.	2.2	2
50	Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV/Hepatitis B virus coinfecting patients from Sub-Saharan Africa. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 634-644.	2.8	31
51	Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw793.	5.8	70
52	Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days. <i>Clinical Infectious Diseases</i> , 2016, 63, 1353-1356.	5.8	201
53	Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. <i>AIDS Research and Therapy</i> , 2016, 13, 27.	1.7	62
54	What Level of Risk Compensation Would Offset the Preventive Effect of Early Antiretroviral Therapy? Simulations From the TEMPRANO Trial. <i>American Journal of Epidemiology</i> , 2016, 184, 755-760.	3.4	1

#	ARTICLE	IF	CITATIONS
55	High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial. <i>AIDS Research and Therapy</i> , 2016, 13, 12.	1.7	61
56	Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. <i>Clinical Infectious Diseases</i> , 2016, 62, 1454-1462.	5.8	14
57	Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 490-496.	3.0	2
58	A 6-Year-Old Child with Severe Ebola Virus Disease: Laboratory-Guided Clinical Care in an Ebola Treatment Center in Guinea. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004393.	3.0	18
59	Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from CÔte d'Ivoire. <i>Antiviral Therapy</i> , 2015, 20, 643-654.	1.0	21
60	Favipiravir for children with Ebola. <i>Lancet, The</i> , 2015, 385, 603-604.	13.7	43
61	Dose regimen of favipiravir for Ebola virus disease. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 150-151.	9.1	86
62	Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis. <i>Lancet HIV,the</i> , 2015, 2, e137-e150.	4.7	61
63	A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. <i>New England Journal of Medicine</i> , 2015, 373, 808-822.	27.0	1,028
64	Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 248-251.	1.8	2
65	New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon. <i>Bulletin of the World Health Organization</i> , 2015, 93, 521-528.	3.3	9
66	Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in CÔte d'Ivoire. <i>Journal of the International AIDS Society</i> , 2014, 17, 18977.	3.0	11
67	Effect of Early Antiretroviral Therapy on Sexual Behaviors and HIV-1 Transmission Risk Among Adults With Diverse Heterosexual Partnership Statuses in CÔte d'Ivoire. <i>Journal of Infectious Diseases</i> , 2014, 209, 431-440.	4.0	36
68	The Survival Benefits of Antiretroviral Therapy in South Africa. <i>Journal of Infectious Diseases</i> , 2014, 209, 491-499.	4.0	32
69	Commentary. <i>Aids</i> , 2014, 28, S101-S104.	2.2	8
70	Genotypic resistance profiles of HIV-2-treated patients in West Africa. <i>Aids</i> , 2014, 28, 1161-1169.	2.2	43
71	Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 294-302.	2.1	7
72	WHO guidelines for antiretroviral therapy in serodiscordant couples in sub-Saharan Africa. <i>Aids</i> , 2014, 28, 1533-1535.	2.2	0

#	ARTICLE	IF	CITATIONS
73	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. <i>HIV Clinical Trials</i> , 2014, 15, 185-198.	2.0	6
74	Quantiferon-TB Gold: Performance for Ruling out Active Tuberculosis in HIV-Infected Adults with High CD4 Count in CÔte d'Ivoire, West Africa. <i>PLoS ONE</i> , 2014, 9, e107245.	2.5	7
75	Increasing Rate of TAMs and Etravirine Resistance in HIV-1-Infected Adults Between 12 and 24 Months of Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 211-219.	2.1	19
76	Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003-2008. <i>BMC Infectious Diseases</i> , 2013, 13, 607.	2.9	6
77	Mortality, AIDS-Morbidity, and Loss to Follow-up by Current CD4 Cell Count Among HIV-1-Infected Adults Receiving Antiretroviral Therapy in Africa and Asia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 555-561.	2.1	44
78	Development of a checklist of quality indicators for clinical trials in resource-limited countries: The French National Agency for Research on AIDS and Viral Hepatitis (ANRS) experience. <i>Clinical Trials</i> , 2013, 10, 300-318.	1.6	7
79	Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. <i>Journal of the International AIDS Society</i> , 2013, 16, 18059.	3.0	8
80	Could Early Antiretroviral Therapy Entail More Risks than Benefits in Sub-Saharan African HIV-Infected Adults? A Model-Based Analysis. <i>Antiviral Therapy</i> , 2013, 18, 45-55.	1.0	17
81	Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The leDEA-West Africa HIV-2 Cohort Study. <i>PLoS ONE</i> , 2013, 8, e66135.	2.5	32
82	AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting Antiretroviral Therapy in CÔte d'Ivoire. <i>Clinical Infectious Diseases</i> , 2012, 54, 714-723.	5.8	84
83	CD4-Specific Mortality Rates Among HIV-Infected Adults With High CD4 Counts and No Antiretroviral Treatment in West Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 213-219.	2.1	11
84	Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. <i>Aids</i> , 2012, 26, 625-634.	2.2	12
85	Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. <i>Cost Effectiveness and Resource Allocation</i> , 2012, 10, 12.	1.5	4
86	Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. <i>World Journal of Hepatology</i> , 2012, 4, 218.	2.0	29
87	HIV treatment and care in resource-constrained environments: challenges for the next decade. <i>Journal of the International AIDS Society</i> , 2012, 15, 17334.	3.0	36
88	Barriers to HIV Testing in CÔte d'Ivoire: The Role of Individual Characteristics and Testing Modalities. <i>PLoS ONE</i> , 2012, 7, e41353.	2.5	43
89	Pregnancy Outcomes in Women Exposed to Efavirenz and Nevirapine: An Appraisal of the leDEA West Africa and ANRS Databases, Abidjan, CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 183-187.	2.1	79
90	CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters. <i>Aids</i> , 2011, 25, 819-823.	2.2	11

#	ARTICLE	IF	CITATIONS
91	Medication Possession Ratio: Predicting and Decreasing Loss to Follow-Up in Antiretroviral Treatment Programs in CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, S34-S39.	2.1	16
92	Association Between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1-Infected Adults on Antiretroviral Therapy in CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 356-364.	2.1	69
93	Comparison of Early CD4 T-Cell Count in HIV-1 Seroconverters in CÔte d'Ivoire and France: The ANRS PRIMO-CI and SEROCO Cohorts. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 260-265.	2.1	10
94	Antiretroviral treatment changes in adults from CÔte d'Ivoire: the roles of tuberculosis and pregnancy. <i>Aids</i> , 2010, 24, 93-99.	2.2	20
95	Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 258-268.	2.1	55
96	Occult HBV infection in untreated HIV-infected adults in CÔte d'Ivoire. <i>Antiviral Therapy</i> , 2010, 15, 1029-1034.	1.0	36
97	CD4 ⁺ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: Projecting beyond clinical trials. <i>Antiviral Therapy</i> , 2010, 15, 351-361.	1.0	8
98	Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis. <i>PLoS Medicine</i> , 2010, 7, e1000382.	8.4	70
99	Co-trimoxazole, cART, and non-AIDS infectious diseases. <i>Lancet, The</i> , 2010, 375, 1231-1233.	13.7	2
100	Short Communication: Severe Symptomatic Hyperlactatemia Among HIV Type 1-Infected Adults on Antiretroviral Therapy in CÔte d'Ivoire. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 991-995.	1.1	2
101	The Financial Burden of Morbidity in HIV-Infected Adults on Antiretroviral Therapy in CÔte d'Ivoire. <i>PLoS ONE</i> , 2010, 5, e11213.	2.5	38
102	Impact of Drug Stock-Outs on Death and Retention to Care among HIV-Infected Patients on Combination Antiretroviral Therapy in Abidjan, CÔte d'Ivoire. <i>PLoS ONE</i> , 2010, 5, e13414.	2.5	106
103	Medium-Term Probability of Success of Antiretroviral Treatment after Early Warning Signs of Treatment Failure in West African Adults. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 783-793.	1.1	7
104	Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A CÔte d'Ivoire Appraisal. <i>PLoS Medicine</i> , 2009, 6, e1000173.	8.4	66
105	Two-Months-off, Four-Months-on Antiretroviral Regimen Increases the Risk of Resistance, Compared with Continuous Therapy: A Randomized Trial Involving West African Adults. <i>Journal of Infectious Diseases</i> , 2009, 199, 66-76.	4.0	31
106	Avascular osteonecrosis of the femoral head in three West African HIV-infected adults with heterozygous sickle cell disease. <i>Antiviral Therapy</i> , 2009, 14, 1011-1014.	1.0	9
107	When to Start Antiretroviral Therapy in Resource-Limited Settings. <i>Annals of Internal Medicine</i> , 2009, 151, 157.	3.9	113
108	Contextual or Universal Ethics: A Non-Issue?. <i>Journal International De Bioethique</i> , 2009, 20, 65.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Depressive Symptoms and Exposure to Efavirenz in West African HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2008, 9, 445-447.	2.0	8
110	Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. <i>Bulletin of the World Health Organization</i> , 2008, 86, 559-567.	3.3	275
111	Rapid scaling-up of antiretroviral therapy in 10 000 adults in CÔte d'Ivoire: 2-year outcomes and determinants. <i>Aids</i> , 2008, 22, 873-882.	2.2	168
112	Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. <i>Aids</i> , 2008, 22, 1897-1908.	2.2	564
113	HIV-1 DNA in Peripheral Blood Mononuclear Cells Is Strongly Associated With HIV-1 Disease Progression in Recently Infected West African Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 350-354.	2.1	44
114	Prophylaxis with co-trimoxazole for HIV infected adults in Africa. <i>BMJ: British Medical Journal</i> , 2008, 337, a304-a304.	2.3	4
115	Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults. <i>Bulletin of the World Health Organization</i> , 2008, 2008, 435-442.	3.3	15
116	Variation of CD4 Count and Percentage during Pregnancy and after Delivery: Implications for HAART Initiation in Resource-Limited Settings. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1469-1474.	1.1	37
117	HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. <i>Aids</i> , 2007, 21, 973-982.	2.2	26
118	Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. <i>Aids</i> , 2007, 21, 2483-2491.	2.2	116
119	Short Communication: Lack of Indinavir-Associated Nephrological Complications in HIV-Infected Adults (Predominantly Women) with High Indinavir Plasma Concentration in Abidjan, CÔte d'Ivoire. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 62-66.	1.1	4
120	Morbidity Before and After HAART Initiation in Sub-Saharan African HIV-Infected Adults: A Recurrent Event Analysis. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1338-1347.	1.1	31
121	HIV-1 Antiretroviral Drug Resistance in Recently Infected Patients in Abidjan, CÔte d'Ivoire: A 4-Year Survey, 2002-2006. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1155-1160.	1.1	29
122	Are a past history of tuberculosis and WHO clinical stage associated with incident tuberculosis in adults receiving antiretroviral therapy?, reply to Lawn et al.. <i>Aids</i> , 2007, 21, 389-390.	2.2	1
123	Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. <i>Aids</i> , 2007, 21, 1157-1164.	2.2	34
124	Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, CÔte d'Ivoire: impact of alternative methods of CD4 count modelling. <i>European Journal of Epidemiology</i> , 2007, 22, 737-744.	5.7	18
125	Field Adherence to Highly Active Antiretroviral Therapy in HIV-Infected Adults in Abidjan, CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 45, 355-358.	2.1	62
126	Progression to WHO criteria for starting antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. <i>Bulletin of the World Health Organization</i> , 2007, 85, 116-123.	3.3	27

#	ARTICLE	IF	CITATIONS
127	The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in CÔte d'Ivoire. <i>Antiviral Therapy</i> , 2007, 12, 543-51.	1.0	36
128	The Independent Effect of Highly Active Antiretroviral Therapy on Severe Opportunistic Disease Incidence and Mortality in HIV-Infected Adults in CÔte D'Ivoire. <i>Antiviral Therapy</i> , 2007, 12, 543-551.	1.0	60
129	CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. <i>Lancet, The</i> , 2006, 367, 1981-1989.	13.7	230
130	The Trivacan study – Authors' reply. <i>Lancet, The</i> , 2006, 368, 916.	13.7	0
131	Tolerance and Acceptability of an Efavirenz-Based Regimen in 740 Adults (Predominantly Women) in West Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 29-35.	2.1	41
132	Nonantiretroviral Drug Consumption by CD4 Cell Count in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 225-231.	2.1	9
133	Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, CÔte d'Ivoire. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2006, 100, 785-790.	1.8	24
134	Risk factors for active tuberculosis in adults on highly active antiretroviral therapy in Africa. <i>Aids</i> , 2006, 20, 1463.	2.2	1
135	Lack of Directly Observed Treatment Affects Tuberculosis Relapse Rates. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 359a-359a.	5.6	0
136	Cost-Effectiveness of HIV Treatment in Resource-Poor Settings – The Case of CÔte d'Ivoire. <i>New England Journal of Medicine</i> , 2006, 355, 1141-1153.	27.0	253
137	Commentary: Decline of HIV-2 prevalence in West Africa: good news or bad news?. <i>International Journal of Epidemiology</i> , 2006, 35, 1329-1330.	1.9	22
138	Stability of ritonavir soft capsule formulation in patients with and without a refrigerator at home in CÔte d'Ivoire. <i>International Journal of STD and AIDS</i> , 2006, 17, 784-785.	1.1	0
139	Risk Factors for Tuberculosis among HIV-infected Patients Receiving Antiretroviral Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 1348a-1349.	5.6	3
140	Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in CÔte d'Ivoire: a trial-based analysis. <i>Aids</i> , 2005, 19, 1299-1308.	2.2	72
141	Risk Factors for Active Tuberculosis after Antiretroviral Treatment Initiation in Abidjan. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 123-127.	5.6	112
142	Use of a Bayesian Approach to Decide When to Stop a Therapeutic Trial: The Case of a Chemoprophylaxis Trial in Human Immunodeficiency Virus Infection. <i>American Journal of Epidemiology</i> , 2005, 161, 595-603.	3.4	5
143	Transfer and Evaluation of an Automated, Low-Cost Real-Time Reverse Transcription-PCR Test for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection in a West African Resource-Limited Setting. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2709-2717.	3.9	221
144	Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in CÔte d'Ivoire: a 7-year cohort study. <i>Aids</i> , 2005, 19, 443-445.	2.2	24

#	ARTICLE	IF	CITATIONS
145	Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in CÔte d'Ivoire. <i>Antiviral Therapy</i> , 2005, 10, 615-24.	1.0	49
146	Haematological Changes in Adults Receiving a Zidovudine-Containing Haart Regimen in Combination with Cotrimoxazole in CÔte D'Ivoire. <i>Antiviral Therapy</i> , 2005, 10, 615-624.	1.0	92
147	High incidence of atypical mycobacteriosis in African HIV-infected adults with low CD4 cell counts. <i>Aids</i> , 2004, 18, 1961-1964.	2.2	17
148	Impact of Vital Status Investigation Procedures on Estimates of Survival in Cohorts of HIV-Infected Patients From Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 35, 320-323.	2.1	53
149	Urinary pH in HIV-infected adults in Ivory Coast and in France. <i>Aids</i> , 2003, 17, 2003-2005.	2.2	7
150	Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, CÔte d'Ivoire. <i>Aids</i> , 2003, 17, 575-584.	2.2	64
151	Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, CÔte d'Ivoire. <i>Antiviral Therapy</i> , 2003, 8, 385-93.	1.0	42
152	Medium-Term Survival, Morbidity and Immunovirological Evolution in HIV-Infected Adults Receiving Antiretroviral Therapy, Abidjan, CÔte D'Ivoire. <i>Antiviral Therapy</i> , 2003, 8, 385-393.	1.0	78
153	Causes and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, CÔte d'Ivoire. <i>Aids</i> , 2002, 16, 909-918.	2.2	30
154	HIV-1 infection and malaria parasitaemia. <i>Lancet, The</i> , 2001, 357, 233.	13.7	0
155	Trimethoprim-sulfamethoxazole prophylaxis in sub-Saharan Africa. <i>Lancet, The</i> , 2001, 358, 1027-1028.	13.7	17
156	Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, CÔte d'Ivoire. <i>Aids</i> , 2001, 15, 869-876.	2.2	15
157	The effect of cotrimoxazole coadministrated with antituberculous drugs on serum transaminases in HIV-infected adults from the Ivory Coast. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 611-612.	2.4	0
158	HIV-1-Related Morbidity in Adults, Abidjan, CÔte d'Ivoire: A Nidus for Bacterial Diseases. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 478-486.	2.1	26
159	Dietary Problems in African HIV-1-Infected Adults, Abidjan, CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 357-358.	2.1	2
160	Dietary Problems in African HIV-1-Infected Adults, Abidjan, CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 357-358.	2.1	0
161	Thresholds of CD4 cells for initiating trimethoprim-sulfamethoxazole prophylaxis in west Africa. <i>Aids</i> , 2000, 14, 2628-2629.	2.2	3
162	Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, CÔte d'Ivoire: a randomised trial. <i>Lancet, The</i> , 1999, 353, 1463-1468.	13.7	392

#	ARTICLE	IF	CITATIONS
163	CD4 count and CD4% in African HIV-infected people. International Journal of Epidemiology, 1998, 27, 928-928.	1.9	2
164	CD4+ T-Lymphocyte Counts in HIV Infection. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 361-363.	0.3	57
165	Tuberculosis and chemoprophylaxis in Africa. Lancet, The, 1995, 345, 867-868.	13.7	6
166	INVASIVE HAEMOPHILUS INFLUENZAE DISEASE OF MELANESIAN AND CALUCASIAN CHILDREN IN NEW CALEDONIA. Pediatric Infectious Disease Journal, 1993, 12, 888.	2.0	6
167	Association of Plasma sVCAM-1 and sCD14 with Mortality in HIV-1 Infected West African Adults with High CD4 Counts. SSRN Electronic Journal, 0, , .	0.4	0